![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Nkx2.2 regulates cell fate choice in the enteroendocrine cell lineages of the intestine 1Department of Biochemistry and Molecular Genetics, University of Colorado at Denver Health Sciences Center, Aurora, Colorado 80045, USA 2Program in Molecular Biology, University of Colorado at Denver Health Sciences Center, Aurora, Colorado 80045, USA * Author for correspondence Lori Sussel (Email: lgs2/at/columbia.edu), Tel. 212-851-5115, Fax. 212-851-5237 3Current address: Department of Genetics and Development, Columbia University College Physicians and Surgeons, 1150 St. Nicholas Avenue Room 607B New York, NY 10032 The publisher's final edited version of this article is available at Dev Biol.Abstract Nkx2.2 is a homeodomain-containing transcription factor essential for pancreatic islet cell specification. In this study we investigate the role of Nkx2.2 within the small intestine. We have determined that Nkx2.2 is expressed at the onset of intestinal epithelial cell differentiation in specific intestinal cell populations, including a subset of enteroendocrine cells. Similar to its role in the pancreatic islet, Nkx2.2 regulates cell fate choices within the intestinal enteroendocrine population; in the Nkx2.2 null mice, several hormone-producing enteroendocrine cell populations are absent or reduced and the ghrelin-producing cell population is upregulated. The remaining intestinal cell populations, including the paneth cells, goblet cells and enterocytes appear to be unaffected by the loss of Nkx2.2. Furthermore, similar to the pancreatic islet, Nkx2.2 appears to function upstream of Pax6 in regulating intestinal cell fates; Pax6 mRNA and protein expression is decreased in the Nkx2.2 null mice. These studies identify a novel role for Nkx2.2 in intestinal endocrine cell development and reveal the regulatory similarities between cell type specification in the pancreatic islet and in the enteroendocrine population of the intestine. Keywords: Nkx2.2, enteroendocrine cells, intestine, ghrelin, hormones, cell type specification Introduction Intestinal development provides an excellent model system for understanding the molecular mechanisms that regulate cell fate decisions during embryogenesis. Numerous studies in a variety of vertebrate species have defined many of the complex developmental events that lead to the formation and differentiation of the intestinal epithelium (reviewed in de Santa Barbara et al., 2003; Hauck et al., 2005; Lee and Kaestner, 2004; Ng et al., 2005; Roberts and Pearson, 2005; Wallace et al., 2005; Walters, 2005). Remarkably, this developmental process is conserved in all vertebrates studied. These cumulative studies have demonstrated the important early patterning events that occur along the anterior-posterior axis to generate regional specification, as well as the numerous signaling pathways that pattern the remaining dorsoventral, left-right, and radial axes to direct general endodermal differentiation. Subsequent differentiation of the endoderm occurs in response to epithelial-mesenchymal interactions and gives rise to the functional epithelium, which becomes organized into villi that project into the gut lumen and the crypts that are embedded in the mesenchyme. The four major differentiated cell types in the small intestine: goblet, enteroendocrine, enterocyte and paneth differentiate from a common pluripotent stem cell, which is located in the crypt (Cheng and Leblond, 1974). As they differentiate, the goblet, enteroendocrine, and enterocyte cell populations migrate from the crypt toward the villus tip, where they eventually die and are extruded into the lumen. The paneth cells migrate downward to reside at the base of the crypt. Within the epithelium, the absorptive enterocytes are the predominant cell type. Of the remaining cell types, the goblet cells secrete mucus, the enteroendocrine cells secrete various hormones and growth factors, and the paneth cells secrete antimicrobial compounds. Although the migration, morphology and functions of each cell population have been well characterized, the molecular mechanisms that regulate the respective cell fate decisions are unknown. The enteroendocrine population only represents approximately 1% of the gut epithelial cells (Cheng and Leblond, 1974); however this constitutes the largest population of hormone producing cells in the body. Furthermore, the intestinal enteroendocrine population is subdivided into at least 15 different cell types, which can be classified on the basis of their morphology, expression of peptide hormone, and specific marker expression. Recently several gene expression and traditional transgenic knockout studies have identified some of the signaling pathways and regulatory factors that are involved in the development and differentiation of the enteroendocrine population (reviewed in (Lee and Kaestner, 2004; Schonhoff et al., 2004). Similar to their neuroendocrine counterparts, Notch signaling plays a critical role in gut endocrine cell fate decisions in the intestine and the pancreas (Apelqvist et al., 1999; Fre et al., 2005; Jensen et al., 2000) and represses the transcription factor Hes1, to allow the initiation of cell differentiation. Subsequently, the bHLH molecules, Math1 and Neurogenin3 (Ngn3) are activated to initiate the endocrine differentiation program (Jenny et al., 2002; Lee et al., 2002; Yang et al., 2001). Further differentiation of the enteroendocrine population into the 15 different subtypes is not well understood, but mouse knockout studies have implicated several different transcription factors in this process. Pdx1, a homeobox protein that is essential for pancreatic development, is required for development of several endocrine populations in the duodenum; serotonin, secretin and cholecystokinin (CCK) are reduced and gastrin is absent in the duodenum of the Pdx1 null mice (Offield et al., 1996). The bHLH protein NeuroD1/Beta2 is essential for the formation of secretin and CCK cells (Naya et al., 1997) and the paired homeodomain factors, Pax4 and Pax6 also affect the differentiation of endocrine subtypes. Pax6 is required for pancreatic glucagon production and the intestinal GLP-1 cell formation. Pax4 is necessary for the production of most endocrine cell types in the small intestine (Hill et al., 1999; Larsson et al., 1998). Remarkably, each of these transcription factors also differentially regulates pancreatic hormone expression and the development of pancreatic hormone-producing islet cells (Miller et al., 1994; Naya et al., 1997; Offield et al., 1996; Ohlsson et al., 1993; Sosa-Pineda et al., 1997; St-Onge et al., 1997), implying a conserved regulatory pathway exists between the respective formation of intestinal and pancreatic endocrine cell populations. Nkx2.2 is a homeodomain transcription factor that is essential for the differentiation of three of the pancreatic endocrine populations (Sussel et al., 1998). In the islets of Nkx2.2 null mice, the insulin, glucagon, and pancreatic polypeptide (PP) populations are absent or reduced, and a population of cells producing the peptide hormone ghrelin is upregulated (Prado et al., 2004). Due to the profound effect of Nkx2.2 on the specification of the islet endocrine populations and the strong regulatory connection between pancreatic and intestinal regulatory pathways, we investigated the role of Nkx2.2 in mouse intestinal development. In this study, we demonstrate that Nkx2.2 is expressed at the onset of intestinal epithelial differentiation in a subset of enteroendocrine cells. This finding is consistent with a recent study in zebrafish that demonstrates Nkx2.2 colocalization with several enteroendocrine hormones in the intestine (Ng et al., 2005). We also determine that in the absence of Nkx2.2, most intestinal hormones in the duodenum and jejunum are absent or reduced and the ghrelin-producing cell population is correspondingly increased, similar to what is observed in the Nkx2.2 null islets. This finding further implicates Nkx2.2 as an important regulator of many endocrine cell populations in the intestine and pancreas, where it plays a critical role in modulating cell fate specification to maintain a normal ratio of endocrine cell populations. Interestingly, although the ultimate endocrine cell identities are distinct within the pancreas and the intestine, the role of Nkx2.2 in the two tissues is remarkably conserved, suggesting that additional lineage-restricted transcription factors will be required to contribute to the terminal differentiation of each endocrine cell population and regulate proper hormone production. Materials and methods Mice Mice were maintained on a Swiss black (Taconic) background and were housed in the University of Colorado Health Sciences Center animal resource center. The mice were fed standard rodent chow and all animal procedures were performed according to UCHSC Institutional Review Board approved protocols. Immunohistochemistry and in situ hybridization Tissue was fixed overnight in 4% paraformaldehyde, cryopreserved and cryosectioned into 10 μm sections. At e18.5, n > 6 mutant embryos for each antibody and RNA in situ probe assayed; at e15.5, n >5 for each RNA in situ probe assayed. In each case, corresponding numbers of wild type littermates were simultaneously analyzed. Immunofluorescence was performed on cryo-preserved tissue with the primary antibodies listed in Table 1. Secondary antibodies include: Alexa-fluor 488, 594, or 305 (Molecular Probes, Eugene, OR; 1:800).
RNA in situ hybridization was performed as previously described on e15.5 and e18.5 tissue (Prado et al., 2004) using antisense riboprobes transcribed from linearized plasmids. Riboprobes for all genes except Nkx2.2 were generated from full-length cDNAs, which were PCR-cloned from e17.5 intestinal RNA. Full-length Nkx2.2 was cloned from a brain cDNA library (Porteus et al., 1992). RNA in situs were performed on tissue from Nkx2.2 null embryos and a corresponding number of wild type littermates: villin (n=5), IFABP (n=4), Cryptdin1 (n=9), Cryptdin 6 (n=6), Cryptdin7 (n=10), Hes1 (n=3), Cdx1 (n=3), Cdx2 (n=3), Tcf4 (n=3), Math1 (n=4), Ngn3 (n=4), NeuroD1 (n=7), Pax6 (n=5) and ghrelin (n=8). Nkx2.2 RNA in situs were performed on e12.5, e13.5, e15.5 and e18.5 tissue. For combined Nkx2.2 RNA in situ and anti-glucagon immunohistochemical analyses, the RNA in situs were performed to completion followed by immunohistochemistry using rabbit anti-glucagon antibody and biotinylated anti-rabbit secondary antibodies (Jackson Immunoresearch). The biotinylated secondary antibodies were visualized using the Vectastain ABC kit (Vector labs). Images were obtained with a Leica DM5000 microscope and a Qimaging Evolution MP Color camera or a Nikon Eclipse 80i microscope and a Qimaging Retiga EXi-Fast 1394 camera, and were processed using ImagePro software from Media Cybernetics. Cell counting The total number of chromograninA, CCK, ghrelin, GIP, glucagon, PYY, secretin, serotonin, PH3 and alcian blue positive cells were individually counted and the total intestinal area was measured using standard morphometric analysis with ImagePro software on every 10th section (10 μm each, 10 sections per embryo) for wild type (ChromograninA, CCK, GIP, glucagon, PH3 and alcian blue: n=3; ghrelin, PYY, secretin, serotonin: n=7) and Nkx2.2-/- e18.5 embryos (ChromograninA, CCK, GIP, glucagon, PH3 and alcian blue: n=3; ghrelin, PYY, secretin, serotonin: n=8). The number of immunoreactive cells per cross section were counted and normalized to the total intestinal area used in the measurements. The results obtained from each embryo were averaged and statistically analyzed. Quantitative real-time PCR Total RNA was extracted from e18.5 wild type and Nkx2.2-/- intestine tissue (dissected between the pyloric sphincter on the anterior end to the caecum, posteriorly) and prepared using the Qiagen RNeasy Micro kit. cDNAs were prepared with random hexamer primers and Superscript III (Invitrogen). Real-time PCR was performed on the ABI 7000 using Taqman probes (ABI Assays on Demand) or individually designed Taqman probes and primers. Each gene was normalized to Gapdh. See Table 2 for the list of primers and Table 3 for the numbers of samples tested for each probe. Samples were quantified with ABI prism software.
Results Nkx2.2 is expressed in scattered cell populations throughout the intestine during embryonic development To determine when and where Nkx2.2 is expressed in the developing mouse intestine, we performed RNA in situ analysis to assess Nkx2.2 mRNA expression patterns throughout embryogenesis. At e12.5, Nkx2.2 is expressed robustly in the dorsal pancreas and in the emerging ventral pancreas, but cannot be detected in the developing intestine (Figure 1a
Nkx2.2 is specifically required for appropriate cell type specification of the enteroendocrine lineages With the discovery that Nkx2.2 is expressed in specific cells of the developing intestine, we wanted to determine whether Nkx2.2 plays a role in intestinal epithelial development and cell type differentiation, similar to its role in the pancreatic islet. For this study, we analyzed mice that had been deleted for Nkx2.2 (Sussel et al., 1998). Because the Nkx2.2 null mice die shortly after birth with pancreatic islet and neural defects (Briscoe et al., 1999; Sussel et al., 1998), our analysis of the intestine was restricted to the late embryonic stages, shortly after differentiation of the intestinal epithelium is initiated. The Nkx2.2 null mice appear to have no gross alterations in their intestinal morphology when assessed by hemotoxylin and eosin (H&E) staining at any stage during embryonic development (Figure 5a and b
Although there is a reduction in many of the hormone-producing cells in the Nkx2.2 null mice, immunohistochemical analysis of the pan-endocrine markers chromograninA and synaptophysin suggested that the total numbers of enteroendocrine cells is unchanged (Figure 3
The loss of several hormone-producing populations and the simultaneous increase in ghrelin-producing cells suggests that the ghrelin cell population may be specified at the expense of the other endocrine cell lineages. However, it remains possible that the loss of Nkx2.2 activity increases the proliferation of the existing ghrelin cell population, independently of losing the other hormone-producing cells. To test this possibility, we analyzed the expression of phospho-Histone H3 to assess the mitotic status of the ghrelin-positive cells. Similar to our results in the pancreatic islet, we could not detect any proliferating ghrelin-positive cells in the intestine of wild-type or Nkx2.2 null embryos (data not shown) and the total number of proliferating cells in the intestine is not significantly altered when we quantified the total number of phospo-histone H3 positive cells (wild type: 216.2±18.6 (n=3); Nkx2.2: 169±11.1 (n=3). Therefore, we hypothesize that in the absence of Nkx2.2 several of the endocrine populations appear to be replaced by ghrelin-producing endocrine cells. Nkx2.2 does not affect the differentiation of the other intestinal cell populations The loss of several hormone-producing enteroendocrine populations and corresponding upregulation of ghrelin cells in the absence of Nkx2.2 activity confirms the importance of Nkx2.2 in intestinal enteroendocrine cell specification. However, because we could not perform co-staining analysis of Nkx2.2 with the other intestinal epithelial cell populations, we could not rule out that Nkx2.2 was either directly or indirectly involved in the development and differentiation of other intestinal cell populations. To determine whether Nkx2.2 affected the development of these remaining intestinal cell types we assessed the expression of characteristic cell-type specific markers during intestinal development (Figure 4 Positioning Nkx2.2 in the intestinal regulatory pathway The increase in ghrelin cells at the expense of the several intestinal endocrine populations has not been reported in other mouse knockout models known to affect intestinal enteroendocrine cell differentiation. To better understand the molecular basis of the defects observed in the Nkx2.2 knockout and to position Nkx2.2 in the hierarchy of transcription factors regulating intestinal cell fates, we assessed expression of many of the regulatory factors known to be involved in intestinal cell differentiation. Several different transcription factors have been shown to regulate the cell type differentiation process of all intestinal cell populations or the enteroendocrine lineages, specifically. We used RNA in situ analysis and quantitative real-time PCR to determine which, if any, of the transcription factors had altered expression in the Nkx2.2 knockout mice (Figure 6 a-l
Many additional transcription factors are thought to be responsible for the correct specification and/or development of several enteroendocrine lineages. Ngn3 and NeuroD1/Beta2 (hereafter referred to as NeuroD1) are basic helix-loop-helix transcription factors that are also involved in the endocrine cell differentiation process. Ngn3 is required for the differentiation of all endocrine cells in the gastrointestinal tract and pancreatic islet; Ngn3 null mice fail to develop these populations. Ngn3 expression is not altered in the Nkx2.2 knockout mice (Figure 6g-h Islet1 (Isl1) and Pdx1 play important regulatory roles in the differentiation of islet and intestinal endocrine populations. It has been suggested that the LIM homeodomain protein, Isl1 is involved in the early differentiation of gastrin and somatostatin cells, however the early lethality associated with the Isl1 knockout mice precludes confirmation of an Isl1 intestinal function (Ahlgren et al., 1997; Larsson, 2000). A deletion of the homeodomain protein, Pdx1, however, results in a loss or reduction of several endocrine cell populations in the duodenum (Larsson et al., 1996). Although the Nkx2.2 knockout affects many of the same endocrine cell populations, the expression of both these genes is unaffected by the loss of Nkx2.2 (Supplemental figure 2). Pax4 and Pax6 are also critical endocrine regulatory factors that, similar to Nkx2.2, have been implicated in both pancreatic and intestinal cell fate determination (Larsson et al., 1998). In the intestine, Pax4 is essential for the formation of serotonin, secretin, CCK, GIP, and PYY cells and Pax6 is required for GIP cell differentiation. Interestingly, although it appears that Pax4 and Nkx2.2 regulate an overlapping set of intestinal cell types, Pax4 expression is not affected in the Nkx2.2 knockout mice (Supplemental figure 2). This would suggest that Pax4 functions upstream of Nkx2.2 or in a parallel pathway for the formation of several different enteroendocrine cell types. This result is consistent with what we observe with corresponding Nkx2.2 and Pax4 functions in the pancreatic islet. Pax6, on the other hand, is down-regulated in the absence of Nkx2.2 (Figure 6k-p Discussion Nkx2.2 has previously been shown to be essential for the appropriate differentiation of ventral spinal cord neurons, oligodendrocytes, and pancreatic islet cells (Briscoe et al., 2000; Prado et al., 2004; Qi et al., 2001; Sussel et al., 1998; Zhou et al., 2001). In this study, we demonstrate that Nkx2.2 is also critical for the appropriate differentiation of enteroendocrine cells in the small intestine. We assessed the protein and/or mRNA expression of many of the hormones produced in the developing small intestine and found that several of endocrine cell populations that populate the proximal small intestine were reduced. Interestingly, these endocrine populations were not completely eliminated, suggesting that Nkx2.2-independent differentiation programs exist, or compensatory mechanisms are sometimes able to operate. Another Nkx family member, Nkx6.1 is also expressed in the small intestine, although analysis of Nkx6.1 in the intestine has not yet been performed. In addition to the reduction of several intestinal hormone-producing populations in the Nkx2.2 knockout, we observed a significant increase in the number of cells expressing ghrelin, suggesting that some enteroendocrine populations may be replaced by the ghrelin-producing cells. This is similar to what is observed in the Nkx2.2 knockout pancreatic islet, where the insulin-producing β cell population and most glucagon-producing α cells are also replaced by the ghrelin cells. This cell type conversion implies that Nkx2.2 plays an early role in specifying endocrine cell identities and, in its absence, the differentiation pathway either defaults or is diverted to the ghrelin cell fate. Alternatively, it is possible that cell fate changes have not occurred in the intestine of Nkx2.2 null mice, but instead Nkx2.2 differentially regulates hormone expression at the transcriptional level; the hormones that are lost would be activated by Nkx2.2 and ghrelin would be repressed by Nkx2.2. While we had additional cell-specific markers to demonstrate that the ghrelin-producing cells in the Nkx2.2 null islet were not molecularly identical to α or β cells, similar molecular tools are not yet available for the intestinal endocrine cell populations. We have, however, determined that Nkx2.2 does not repress transcription of the mouse or human ghrelin promoter in αTC and HCT8 cell lines, which both express ghrelin endogenously (Christina Chao and Lori Sussel, unpublished data). Further analysis of the individual enteroendocrine populations affected in the Nkx2.2 null mice will be necessary to determine the mechanism by which Nkx2.2 functions to regulate endocrine cell fates and hormone expression in the intestine. Similar to many of the other intestinal transcription factors, which predominantly regulate the development of small subsets of enteroendocine cell populations, deletion of Nkx2.2 does not affect all hormone-producing endocrine populations in the small intestine. Furthermore, the affected endocrine cell populations are variably reduced. This is similar to what is observed in the pancreatic islet, where Nkx2.2 is required for the formation of all insulin-producing β cells, and only subsets of the glucagon-producing α cells and PP cells. This would suggest that unlike Ngn3, Nkx2.2 is not a global regulator of the endocrine cell populations, but functions a later stage to specify the differentiation of specific endocrine cell fates. Interestingly, Nkx2.2 is not required for the formation of the somatostatin-expressing δ cell population in the islet, whereas it is required for the expression of somatostatin in the intestine. This further underscores that while there are obvious similarities between the endocrine cell populations in the intestine and pancreas, fundamental regulatory differences exist in each cell type as well. It is interesting, however, that the ghrelin cell population is upregulated in both the islet and small intestine when Nkx2.2 is deleted. This suggests that mechanism by which Nkx2.2 controls some of the early general fate decisions in the pancreas and intestine are conserved. Consistent with this, several other transcription factors commonly regulate cell fate decisions in the islet and intestine (reviewed in Lee and Kaestner, 2004; Schonhoff et al., 2004). Furthermore, our study has demonstrated that portions of the transcriptional regulatory pathway may also be conserved between the two tissues: in Nkx2.2-deficient pancreas and intestine, Pdx1, Ngn3 and Pax4 expression is unaffected, while Pax6 and NeuroD1 expression is reduced. What is remarkable about this conservation is that the ultimate cell fates and hormone products of the islet and gut endocrine cells are different. We propose that although these common regulatory factors may contribute to the final cell fate decisions, unique combinations of additional tissue and cell type specific proteins will be required to initiate the different terminal differentiation pathways and differential hormone expression. Currently there is limited information regarding the lineage relationships between the many enteroendocrine populations; these types of analyses will be essential to unraveling the regulatory pathways and cell fate decision processes that distinguish islet and intestinal endocrine populations, as well as the events that regulate differentiation of each endocrine cell subpopulation. However, the similarities between early islet and intestinal endocrine differentiation regulatory pathways also suggests that the well-characterized intestinal stem cell population could be harnessed to produce alternative sources of islet cells for therapeutic purposes. 01: Supplemental figure 1. Wild type and Nkx2.2-/- ghrelin-expressing cells appear to be endocrine cells Co-immunofluorescent staining of ghrelin-positive cells (green) and the pan-endocrine marker, synaptophysin (red) in the small intestine of wild type and Nkx2.2 null embryos at e18.5. Click here to view.(1.3M, pdf) 02: Supplemental figure 2. Relative transcription factor expression in Nkx2.2 wild type and mutant embryos Real time PCR analysis of transcription factor mRNA isolated from wild type and Nkx2.2 null tissue. See Table 2 for the probe sets. See Table 3 for of embryonic samples tested. Fold change normalized to wild type; * p < 0.01. Click here to view.(89K, pdf) 03: Table 3. Distribution of enteroendocrine cells in e18.5 wild type and Nkx2.2 null gastrointestinal tract Number of immuno-positive cells per cross-section (x±SEM). To quanitify the cells expressing each hormone, 10 cross sections of an embryo were examined for each hormone. The number of immunoreactive cells per cross section was counted and the results averaged. Click here to view.(68K, doc) Acknowledgments We would like to thank the Dr. Kristin Artinger and the Sussel lab for critical reading of this manuscript. This research was supported by the NIH NIDDK and the American Diabetes Association (L.S.), and a T32 training award to MD. Additional support was provided by the University of Colorado Cancer Center Transgenic/Knockout Core and the Diabetes and Endocrinology Research Center (NIH P30 DK57516). Footnotes Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
Cell Mol Life Sci. 2003 Jul; 60(7):1322-32.
[Cell Mol Life Sci. 2003]Birth Defects Res C Embryo Today. 2005 Mar; 75(1):58-71.
[Birth Defects Res C Embryo Today. 2005]Best Pract Res Clin Endocrinol Metab. 2004 Dec; 18(4):453-62.
[Best Pract Res Clin Endocrinol Metab. 2004]Dev Biol. 2005 Oct 1; 286(1):114-35.
[Dev Biol. 2005]J Fish Dis. 2005 Jul; 28(7):383-90.
[J Fish Dis. 2005]Am J Anat. 1974 Dec; 141(4):503-19.
[Am J Anat. 1974]Best Pract Res Clin Endocrinol Metab. 2004 Dec; 18(4):453-62.
[Best Pract Res Clin Endocrinol Metab. 2004]Endocrinology. 2004 Jun; 145(6):2639-44.
[Endocrinology. 2004]Nature. 1999 Aug 26; 400(6747):877-81.
[Nature. 1999]Nature. 2005 Jun 16; 435(7044):964-8.
[Nature. 2005]Development. 1998 Jun; 125(12):2213-21.
[Development. 1998]Proc Natl Acad Sci U S A. 2004 Mar 2; 101(9):2924-9.
[Proc Natl Acad Sci U S A. 2004]Dev Biol. 2005 Oct 1; 286(1):114-35.
[Dev Biol. 2005]Proc Natl Acad Sci U S A. 2004 Mar 2; 101(9):2924-9.
[Proc Natl Acad Sci U S A. 2004]Brain Res Mol Brain Res. 1992 Jan; 12(1-3):7-22.
[Brain Res Mol Brain Res. 1992]Development. 1998 Jun; 125(12):2213-21.
[Development. 1998]Dev Biol. 2005 Oct 1; 286(1):114-35.
[Dev Biol. 2005]Development. 1998 Jun; 125(12):2213-21.
[Development. 1998]Nature. 1999 Apr 15; 398(6728):622-7.
[Nature. 1999]Dev Dyn. 2002 May; 224(1):90-102.
[Dev Dyn. 2002]Development. 2002 Jun; 129(11):2619-28.
[Development. 2002]Dev Biol. 2006 Oct 15; 298(2):415-29.
[Dev Biol. 2006]J Mol Histol. 2005 Feb; 36(1-2):15-24.
[J Mol Histol. 2005]Mol Cell Biol. 2000 May; 20(9):3292-307.
[Mol Cell Biol. 2000]EMBO J. 2002 Dec 2; 21(23):6338-47.
[EMBO J. 2002]Genes Dev. 1997 Sep 15; 11(18):2323-34.
[Genes Dev. 1997]Nature. 1997 Jan 16; 385(6613):257-60.
[Nature. 1997]Microsc Res Tech. 2000 Mar 1; 48(5):272-81.
[Microsc Res Tech. 2000]Mech Dev. 1996 Dec; 60(2):175-84.
[Mech Dev. 1996]Mech Dev. 1998 Dec; 79(1-2):153-9.
[Mech Dev. 1998]Cell. 2000 May 12; 101(4):435-45.
[Cell. 2000]Proc Natl Acad Sci U S A. 2004 Mar 2; 101(9):2924-9.
[Proc Natl Acad Sci U S A. 2004]Development. 2001 Jul; 128(14):2723-33.
[Development. 2001]Development. 1998 Jun; 125(12):2213-21.
[Development. 1998]Neuron. 2001 Sep 13; 31(5):791-807.
[Neuron. 2001]Best Pract Res Clin Endocrinol Metab. 2004 Dec; 18(4):453-62.
[Best Pract Res Clin Endocrinol Metab. 2004]Endocrinology. 2004 Jun; 145(6):2639-44.
[Endocrinology. 2004]